Cargando…

Risk factor assessment in high-risk, bacillus Calmette–Guérin-treated, non-muscle-invasive bladder cancer

OBJECTIVE: To assess the risk factors associated with recurrence, progression and survival in high-risk non-muscle-invasive bladder cancer (NMIBC) patients treated with bacillus Calmette–Guérin (BCG) and validate the European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Holz, Serge, Albisinni, Simone, Gilsoul, Jacques, Pirson, Michel, Duthie, Véronique, Quackels, Thierry, Vanden Bossche, Marc, Roumeguère, Thierry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628686/ https://www.ncbi.nlm.nih.gov/pubmed/29034222 http://dx.doi.org/10.2147/RRU.S143865

Ejemplares similares

Bacillus Calmette-Guérin in the management of superficial bladder cancer
por: Kapoor, Rakesh, et al.
Publicado: (2008)

(18)F-JK-PSMA-7 PET/CT for staging intermediate- or high-risk prostate cancer patients before radical prostatectomy: a pilot study
por: Vierasu, Irina, et al.
Publicado: (2023)

Predictive biomarkers of response to bacillus Calmette‐Guérin immunotherapy and bacillus Calmette‐Guérin failure for non‐muscle invasive bladder cancer
por: Wang, Ziting, et al.
Publicado: (2022)

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update
por: Guallar-Garrido, Sandra, et al.
Publicado: (2020)

Bacillus Calmette-Guérin (BCG) Brazilian Backstage in Bladder Cancer
Publicado: (2021)

100 years of the Bacillus Calmette-Guérin vaccine
por: Bettencourt, Paulo J.G., et al.
Publicado: (2021)

Combination of Intravesical Chemotherapy and Bacillus Calmette–Guerin Versus Bacillus Calmette–Guerin Monotherapy in Intermediate- and High-risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016)

Disseminated Bacillus Calmette-Guérin Infection and Immunodeficiency
por: Bernatowska, Ewa Anna, et al.
Publicado: (2007)

Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021)

Validated Prospective Assessment of Quality of Life After Robot-Assisted Laparoscopic Prostatectomy: Beyond Continence and Erections
por: Albisinni, Simone, et al.
Publicado: (2019)

Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)
por: Saban, Marcia R, et al.
Publicado: (2007)

Intravesical bacillus Calmette-Guérin for bladder cancer: are all the strains equal?
por: D’Andrea, David, et al.
Publicado: (2019)

Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer
por: Rachakonda, Tara, et al.
Publicado: (2017)

Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer
por: Miyazaki, Masashi, et al.
Publicado: (2016)

Systemic Granulomatous Reaction Secondary to Treatment of Bladder Cancer with Bacillus Calmette-Guerin
por: Valentini, Caterina Giovanna, et al.
Publicado: (2012)

VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951)

Bacillus Calmette-Guerin (BCG) vaccine in Iran
por: Fallah, Fatemeh, et al.
Publicado: (2018)

Bacillus Calmette-Guerin (BCG): the adroit vaccine
por: Adesanya, Oluwafolajimi A., et al.
Publicado: (2021)

Bacillus Calmette-Guerin Vaccine and Nonspecific Immunity
por: Parmar, Kanak, et al.
Publicado: (2021)

Clinical Course of Bacillus Calmette-Guerin Lymphadenitis
por: Ko, Dayoung, et al.
Publicado: (2022)

AB152. Combination of intravesical chemotherapy and Bacillus Calmette-Guerin versus Bacillus Calmette-Guerin monotherapy in intermediate- and high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis
por: Cui, Jianfeng, et al.
Publicado: (2016)

Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure
por: Shantharam, Govind, et al.
Publicado: (2021)

Clinical experience with (18)F-JK-PSMA-7 when using a digital PET/CT
por: Vierasu, Irina, et al.
Publicado: (2022)

Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin
por: Soylu, Aliye, et al.
Publicado: (2009)

Intravesical bacillus Calmette-Guerin for bladder cancer: What is known? What is not? What is next?
por: Madbouly, Khaled
Publicado: (2013)

Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer
por: Liu, Yuqing, et al.
Publicado: (2019)

Efficacy and safety of Bacillus Calmette-Guerin for bladder cancer: A protocol of systematic review
por: Zhang, Zhi-hui, et al.
Publicado: (2020)

Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer
por: Suh, Jungyo, et al.
Publicado: (2020)

Emerging treatments for bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer
por: Kim, Hyung Suk, et al.
Publicado: (2021)

Treatment strategies for the Bacillus Calmette-Guérin–unresponsive non-muscle invasive bladder cancer
por: Jeong, Seung-hwan, et al.
Publicado: (2023)

THE HOST RESPONSE TO CALMETTE-GUÉRIN BACILLUS INFECTION IN MICE
por: Blanden, R. V., et al.
Publicado: (1969)

Sternal Osteomyelitis after Bacillus Calmette-Guérin Vaccination
por: Selvestravičius, Rolandas, et al.
Publicado: (2016)

Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin
por: Li, Roger, et al.
Publicado: (2020)

COVID-19 and Bacillus Calmette-Guérin: What is the Link?
por: Hegarty, Paul K., et al.
Publicado: (2020)

Bacillus Calmette–Guérin in Immuno-Regulation of Alzheimer’s Disease
por: Klein, Benjamin Y., et al.
Publicado: (2022)

Analysis of risk factors for post-bacillus Calmette–Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer
por: Kim, Tae Jin, et al.
Publicado: (2020)

The role of Bacillus Calmette-Guérin administration on the risk of dementia in bladder cancer patients: a systematic review and meta-analysis
por: Han, Chao, et al.
Publicado: (2023)

Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin
por: Alkhateeb, Sultan S., et al.
Publicado: (2011)

Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing.
por: Pryor, K., et al.
Publicado: (1995)

Mycobacterium bovis Bacillus Calmette-Guérin-Induced Macrophage Cytotoxicity against Bladder Cancer Cells
por: Luo, Yi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9l2sfiufsqlaps036tdprst80d